La chaîne d'options affiche les données clés des options sur actions de Branchout Food à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Branchout Food..

Branchout Food (NASDAQ:BOF) Stock, Chaîne d'Options

Branchout Food

Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are primarily located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.

Branchout Food inc

Kyoto Financial Group Inc

B of A Securities analyst Jason Gerberry maintains Immunovant (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>) with a Buy and lowers the price target from $38 to $33.

News

Price Target

Analyst Ratings

IMVT

B of A Securities Maintains Buy on Immunovant, Lowers Price Target to $33

HTHT

H World Expects To Open Around 2,300 Hotels And Close Around 600 Hotels In FY25

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Liquidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) with a Buy and maintains $29 price target.

Reiteration

LQDA

HC Wainwright & Co. Reiterates Buy on Liquidia, Maintains $29 Price Target

Raymond James analyst Frank Louthan upgrades GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) from Outperform to Strong Buy and maintains the price target from $53 to $53.

Upgrades

Raymond James Upgrades GDS Holdings to Strong Buy, Maintains Price Target to $53

H World Expects Q1 2025 Revenue Growth To Be In The Range Of 0%-4%, For FY25 H World Expects Revenue Growth In The Range Of 2%-6%

On Thursday, Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) announced the acquisition of&nbsp;R&amp;D operations of Xbrane Biopharma AB along with a biosimilar candidate, XB003, which is based on Cimzia (certolizumab pegol) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44410773/alvotech-acquires-xbranes-r-d-operations-in-sweden-and-further-affirms-its-global-leadership-posit" rel="noreferrer noopener">for around SEK275 million (around $27 million)</a>.
The transaction includes a cash payment of SEK102.2 million at closing, along with the assumption of SEK172.8 million in debt and accounts payable.
The creditors have agreed to receive Alvotech equity shares as payment for SEK152.8 million of the debt.
This acquisition enhances Alvotech&#8217;s development capabilities and marks its expansion into Sweden&#8217;s life sciences sector.
The deal includes Xbrane&#8217;s research facilities at Campus Solna near the Karolinska Institute in Stockholm, while Xbrane will retain its other preclinical assets and concentrate on commercialization.
Alvotech is also exploring the possibility of listing Swedish Depository Receipts (SDRs) on Nasdaq Stockholm in the future.
The deal is expected to close in April 2025, subject to approval from relevant regulatory authorities and Xbrane&#8217;s shareholders.
Robert Wessman, founder, Chairman and CEO of Alvotech said,&#8221; &#8220;Furthermore, we will establish a strong presence for Alvotech in the Swedish life science sector, which rivals the U.S. in this field. It will allow Alvotech to attract new talent, create opportunities for scientific collaboration, and support our growth. This is yet another milestone for Alvotech in establishing us as a leader in biosimilars development and production globally.&#8221;
Martin Åmark, CEO of Xbrane stated, &#8220;With this transaction Xbrane is significantly strengthening its financial position and retains over 75% of the competitively adjusted addressable market of the portfolio including Ximluci (Lucentis biosimilar candidate) currently being approved and sold in Europe as well as Xdivane (Opdivo biosimilar candidate), recently partnered with Intas.&#8221;
&#8220;Xbrane will, with a more lean and flexible organization after the transaction, be better equipped to fully focus on realizing the full value of Ximluci and Xdivane with the ambition to generate meaningful royalties/profit sharing from these programs in the years to come.&#8221;
Price Action: ALVO shares closed at $11.34 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44402292/wedbush-expects-lennars-q1-housing-margins-to-dip-amid-mortgage-rate-volatility" target="_blank" rel="noreferrer noopener">Analyst Takes A Cautious View On Lennar Ahead Of Q1 Earnings &#8211; Here&#8217;s Why</a></li>
</ul>
Photo via Shutterstock.

Equities

Mid Cap

ALVO

Alvotech Strengthens Biosimilar Portfolio With $27 Million Xbrane R&D Deal

Yiren Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YRD#NYSE">YRD</a>) reported quarterly earnings of $0.52 per share. This is a 42.46 percent decrease over earnings of $0.91 per share from the same period last year. The company reported $198.95 million in sales this quarter. This is a 10.85 percent increase over sales of $179.48 million the same period last year.

Earnings

Yiren Digital Q4 GAAP EPS $0.52 Down From $0.91 YoY, Sales $198.95M Up From $179.48M YoY

Earnings Beats

Earnings Misses

Rwe Ag Ord Bearer Dm5 American Depository Receipt

RWEOY

RWE reported Q4 Adj EPS $0.97, Sales $8.83B

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and maintains $77 price target.

CAPR

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $77 Price Target

Nvidia&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO, Jensen Huang, has projected the widespread deployment of humanoid robots in manufacturing units in the next five years. This prediction was made public during a keynote speech at Nvidia&#8217;s&nbsp;annual developer conference in San&nbsp;Jose, California on Tuesday.
What Happened: Huang, in his address, unveiled software tools aimed at enhancing the navigation capabilities of humanoid robots. He suggested that the emergence of humanoid robots is a key indicator of AI becoming pervasive.
In terms of timeline, Huang stated it may be &#8220;when, literally, humanoid robots are wandering around, which is not five years away. This is not five-years-away problem, this is a few-years-away problem.&#8221;
According to Huang, the manufacturing industry is likely to be the first to adopt humanoid robots extensively. He argued that factory tasks are clearly defined and performed in a controlled environment, which simplifies automation.
&#8220;I think it ought to go to factories first. And the reason for that is because the domain is much more guard-railed, and the use case is much more specific,&#8221; Huang stated.
As for the economics, the Nvidia CEO stated, &#8220;The value of it is very, very easy to determine. The going rate for renting a human robot is probably $100,000 and I think it&#8217;s pretty good economics.&#8221;
SEE ALSO: <a href="https://www.benzinga.com/media/25/03/44411733/pebble-founder-echoes-mark-zuckerbergs-concerns-slams-apple-for-making-it-nearly-impossible-to-build-smartwatches-that-work-with-iphone">Pebble Founder Echoes Mark Zuckerberg&#8217;s Concerns, Slams Apple For Making It &#8216;Nearly Impossible&#8217; To Build Smartwatches That Work With iPhone</a>
Why It Matters: In August, Morgan Stanley predicted that by 2030, 40,000 humanoids will be working alongside humans in the U.S., with that figure expected to surge to 8 million by 2040 and 63 million by 2055.
Meanwhile, on Wednesday, Ming Hsun Lee from Bank of America Securities <a href="https://www.cnbc.com/video/2025/03/19/component-costs-of-humanoid-robots-will-decline-analyst.html">told</a> CNBC that the decline in component costs of humanoid robots will be &#8216;very fast&#8217; in the next few years leading to widespread adoption.
These predictions resonate with that of Huang and also come on the heels of Nvidia&#8217;s recent unveiling of Groot N1, a new foundation model for humanoid robots. This AI brain<a href="https://www.benzinga.com/tech/25/03/44390580/nvidia-just-unveiled-a-humanoid-ai-brain-which-allows-robots-to-think-slow-jensen-huang-says-this-could-very-well-likely-be-the-largest-industry-of-all"> mimics human cognition </a>and could help address the growing labor gap.
Huang referred to this development as a significant stride in embodied AI. The introduction of humanoid robots in the manufacturing sector could potentially revolutionize the industry, marking a new era of automation and efficiency. Also, this evolution presents a great opportunity for Nvidia to capture. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="GTC March 2025 Keynote with NVIDIA CEO Jensen Huang" width="500" height="281" src="https://www.youtube.com/embed/_waPvOwL9Z8?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
NVDA stock climbed 1.8% to close at $117.52 on Wednesday. The stock lost more than 15% year-to-date, as per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/equities/25/03/44411294/amazon-takes-on-used-car-market-expands-its-auto-platform-to-68-markets-report">Amazon Takes On Used Car Market, Expands Its Auto Platform To 68 Markets: Report</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Tech

NVDA

Nvidia CEO Jensen Huang Sees Humanoid Robots In Factories In Less Than 5 Years: 'I Think It's Pretty Good Economics'

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) with a Buy and lowers the price target from $19 to $15.

ALMS

HC Wainwright & Co. Reiterates Buy on Alumis, Lowers Price Target to $15

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Korro Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) with a Buy and maintains $115 price target.

KRRO

HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $115 Price Target

H World Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.27 by 48.15 percent. This is a 51.72 percent decrease over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $825.00 million which beat the analyst consensus estimate of $798.17 million by 3.36 percent. This is a 4.96 percent increase over sales of $786.00 million the same period last year.

H World Group Q4 Adj $0.14 Misses $0.27 Estimate, Sales $825.00M Beat $798.17M Estimate

Guidance

SCVL

Shoe Carnival Sees FY25 EPS Of $1.60 - $2.10 Vs. $3.32 Est.

Shoe Carnival Sees FY25 Revenue Of $1.15B - $1.23B Vs. $1.24B Est.

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy and maintains $25 price target.

MDWD

HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $25 Price Target

Fiscal 2025 Expectations (with reference to most recent previous guidance):
<ul>
<li>Organic ASV is expected to grow in the range of $100 million to $130 million during fiscal 2025 (narrowing from $90 million to $140 million).</li>
<li>GAAP revenues are expected to be in the range of $2,305 million to $2,325 million (up from $2,285 million to $2,305 million).</li>
<li>GAAP operating margin is expected to be in the range of 32.0% to 33.0% (down from 32.5% to 33.5%).</li>
<li>Adjusted operating margin is expected to be in the range of 36.0% to 37.0% (unchanged).</li>
<li>FactSet's annual effective tax rate is expected to be in the range of 17% to 18% (unchanged).</li>
<li>GAAP diluted EPS is expected to be in the range of $14.80 to $15.40 (down from $15.10 to $15.70).</li>
<li>Adjusted diluted EPS is expected to be in the range of $16.80 to $17.40 (unchanged).</li>
</ul>

FactSet 2025 Outlook: Cuts GAAP EPS Guidance To $14.80-$15.40 (Down From $15.10-$15.70) Vs. $15.63 Est.; Reaffirms Adjusted EPS Of $16.80-$17.40 Vs. $17.16 Est.

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates scPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPH#NASDAQ">SCPH</a>) with a Buy and maintains $18 price target.

SCPH

HC Wainwright & Co. Reiterates Buy on scPharmaceuticals, Maintains $18 Price Target

Dividends

Shoe Carnival Board of Directors Approve 11.1% Increase In Quarterly Dividend To $0.15

FactSet 2025 Outlook: Raised GAAP Revenues Guidance To $2.305B-$2.325M (Up From $2.285B-$2.305B) Vs. $2.309B Est.; Reiterated Adjusted Operating Margin Of 36.0%-37.0%

Financing

Press Releases

BranchOut Food Announces Closing of $1.4 Million Follow-On Public Offering

BranchOut Food Inc. Announces $3.925M CEO-led Investment Including an Insider PIPE and Convertible note

Restaurants

General

BranchOut Food Delivers Shareholder Update: 2024 Revenue Surges 640% in First Half, Poised for Continued Growth and Debt Elimination by Q4 2025

A New Standard in Drug Testing: Intelligent Bio (NASDAQ: INBS) Delivering Cost-Efficiency, Rapid Results, and Employee Dignity more stocks inside…

BranchOut Food Shareholder Update: Projects $15M Run Rate and Positive Cash Flow for Q1 2025 Amid Surge in New Orders as Peru Factory Opens

BranchOut Food Inc. Signs LOI and receives $250K PO from Leading Ingredient Distributor, Definitive Agreement Targeting $5-6M in 2025 Ingredient Sales

BranchOut Food Projects $9 Million in H1 2025 Revenue, Highlighted by $4 Million from Nation's Largest Warehouse Club

Management

BranchOut Food Welcomes Jesse Thomas as Chief Brand Officer to Drive Direct-to-Consumer and Brand Strategy

BranchOut Food Secures $600K+ Order from the Midwest Region of the Nation's Largest Warehouse Club, Driving Bell Pepper Crisps Expansion Across Four Regions

BranchOut Food Signs Definitive Agreement with MicroDried to Revolutionize the $36 Billion Dried Ingredient Market, Projecting $5-6 Million Annual Revenue Surge

Comments

Branchout Food

Branchout Food (BOF) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL